96 related articles for article (PubMed ID: 24906541)
1. The Combination of Elevated Triglycerides and Abnormal Fasting Glucose Increases Risk of Cerebral Infarction in Patients With Mild to Moderate Hypercholesterolemia: A Post Hoc Analysis of the MEGA Study.
Nakagami T; Nishimura R; Sone H; Tajima N
J Cardiovasc Pharmacol Ther; 2015 Mar; 20(2):169-73. PubMed ID: 24906541
[TBL] [Abstract][Full Text] [Related]
2. Pravastatin reduces the risk for cardiovascular disease in Japanese hypercholesterolemic patients with impaired fasting glucose or diabetes: diabetes subanalysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study.
Tajima N; Kurata H; Nakaya N; Mizuno K; Ohashi Y; Kushiro T; Teramoto T; Uchiyama S; Nakamura H;
Atherosclerosis; 2008 Aug; 199(2):455-62. PubMed ID: 18635188
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular and cancer events in hyper-high-density lipoprotein cholesterolemic patients: a post hoc analysis of the MEGA study.
Nakamura H; Mizuno K;
Lipids Health Dis; 2014 Aug; 13():133. PubMed ID: 25135178
[TBL] [Abstract][Full Text] [Related]
4. Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study.
Kushiro T; Mizuno K; Nakaya N; Ohashi Y; Tajima N; Teramoto T; Uchiyama S; Nakamura H;
Hypertension; 2009 Feb; 53(2):135-41. PubMed ID: 19104004
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study).
Mizuno K; Nakaya N; Ohashi Y; Tajima N; Kushiro T; Teramoto T; Uchiyama S; Nakamura H;
Circulation; 2008 Jan; 117(4):494-502. PubMed ID: 18172039
[TBL] [Abstract][Full Text] [Related]
6. Comparison of lipid parameters to predict cardiovascular events in Japanese mild-to-moderate hypercholesterolemic patients with and without type 2 diabetes: Subanalysis of the MEGA study.
Sone H; Nakagami T; Nishimura R; Tajima N;
Diabetes Res Clin Pract; 2016 Mar; 113():14-22. PubMed ID: 26972955
[TBL] [Abstract][Full Text] [Related]
7. Preventive effect of pravastatin on the development of hypertension in patients with hypercholesterolemia: A post-hoc analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study.
Otsuka T; Mizuno K; Shinozaki T; Kachi Y; Nakamura H
J Clin Lipidol; 2017; 11(4):998-1006. PubMed ID: 28655522
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of LDL-C-related parameters to predict cardiovascular risk and effect of pravastatin in mild-to-moderate hypercholesterolemia.
Mizuno K; Nakaya N; Teramoto T; Yokoyama S; Ohashi Y; Ueki A; Takahashi S; Kubota Y; Nakamura H
J Atheroscler Thromb; 2012; 19(2):176-85. PubMed ID: 22129522
[TBL] [Abstract][Full Text] [Related]
9. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
10. A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women.
Davidson MH; Testolin LM; Maki KC; von Duvillard S; Drennan KB
Arch Intern Med; 1997 Jun; 157(11):1186-92. PubMed ID: 9183229
[TBL] [Abstract][Full Text] [Related]
11. Oat-derived beta-glucan significantly improves HDLC and diminishes LDLC and non-HDL cholesterol in overweight individuals with mild hypercholesterolemia.
Reyna-Villasmil N; Bermúdez-Pirela V; Mengual-Moreno E; Arias N; Cano-Ponce C; Leal-Gonzalez E; Souki A; Inglett GE; Israili ZH; Hernández-Hernández R; Valasco M; Arraiz N
Am J Ther; 2007; 14(2):203-12. PubMed ID: 17414591
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for stroke and lipid-lowering effect of pravastatin on the risk of stroke in Japanese patients with hypercholesterolemia: analysis of data from the MEGA Study, a large randomized controlled trial.
Uchiyama S; Nakaya N; Mizuno K; Ohashi Y; Tajima N; Kushiro T; Teramoto T; Nakamura H;
J Neurol Sci; 2009 Sep; 284(1-2):72-6. PubMed ID: 19423132
[TBL] [Abstract][Full Text] [Related]
13. The effect of low-dose pravastatin in metabolic syndrome for primary prevention of cardiovascular disease in Japan: a post hoc analysis of the MEGA study.
Matsushima T; Nakaya N; Mizuno K; Ohashi Y; Teramoto T; Yokoyama S; Ichikawa S; Ishikura N; Kamiyama K; Nakamura H;
J Cardiovasc Pharmacol Ther; 2012 Jun; 17(2):153-8. PubMed ID: 22573644
[TBL] [Abstract][Full Text] [Related]
14. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
[TBL] [Abstract][Full Text] [Related]
15. Primary prevention of cardiovascular diseases among hypercholesterolemic Japanese with a low dose of pravastatin.
Nakamura H;
Atheroscler Suppl; 2007 Aug; 8(2):13-7. PubMed ID: 17586102
[TBL] [Abstract][Full Text] [Related]
16. Low-dose pravastatin and age-related differences in risk factors for cardiovascular disease in hypercholesterolaemic Japanese: analysis of the management of elevated cholesterol in the primary prevention group of adult Japanese (MEGA study).
Nakaya N; Mizuno K; Ohashi Y; Teramoto T; Yokoyama S; Hirahara K; Mizutani M; Nakamura H;
Drugs Aging; 2011 Sep; 28(9):681-92. PubMed ID: 21815708
[TBL] [Abstract][Full Text] [Related]
17. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
Stender S; Schuster H; Barter P; Watkins C; Kallend D;
Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
[TBL] [Abstract][Full Text] [Related]
18. Risk reductions for cardiovascular disease with pravastatin treatment by dyslipidemia phenotype: a post hoc analysis of the MEGA Study.
Nishiwaki M; Ikewaki K; Ayaori M; Mizuno K; Ohashi Y; Ohsuzu F; Ishikawa T; Nakamura H;
J Cardiol; 2013 Mar; 61(3):196-200. PubMed ID: 23265677
[TBL] [Abstract][Full Text] [Related]
19. Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease.
Faergeman O; Holme I; Fayyad R; Bhatia S; Grundy SM; Kastelein JJ; LaRosa JC; Larsen ML; Lindahl C; Olsson AG; Tikkanen MJ; Waters DD; Pedersen TR;
Am J Cardiol; 2009 Aug; 104(4):459-63. PubMed ID: 19660594
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus.
Gutierrez MJ; Rosenberg NL; Macdougall DE; Hanselman JC; Margulies JR; Strange P; Milad MA; McBride SJ; Newton RS
Arterioscler Thromb Vasc Biol; 2014 Mar; 34(3):676-83. PubMed ID: 24385236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
